Psilocybin and Neuroplasticity: What the Science Actually Shows
"Neuroplasticity" has become one of the most frequently cited reasons people are interested in psilocybin therapy. The claim sounds compelling: psilocybin helps the brain rewire itself, forming new connections and breaking old, rigid patterns. But what does the science actually show, and where does hype outpace evidence?
This article separates established findings from promising but preliminary research.
What Neuroplasticity Means
Neuroplasticity is a broad term for the brain's ability to change its structure and function in response to experience. It encompasses several distinct processes:
- Synaptogenesis: the formation of new synaptic connections between neurons
- Dendritic growth: the elaboration of the branching structures through which neurons receive input
- BDNF upregulation: increased production of brain-derived neurotrophic factor, a protein that supports neuron growth and survival
- Functional connectivity changes: shifts in which brain regions communicate with each other
Psilocybin has been associated with all of these — but the evidence is stronger for some than others.
What Preclinical Research Shows
The most direct neuroplasticity evidence comes from animal studies and cell culture experiments, where researchers can directly measure structural changes.
A landmark 2021 study by Ly and colleagues at UC Davis found that psilocybin and related psychedelics promoted structural plasticity in cortical neurons — specifically, increased dendritic spine density and synaptogenesis. These effects were observed at doses that produced only mild behavioral changes, suggesting neuroplasticity may occur below the threshold of a full psychedelic experience.
This research was replicated and extended in subsequent studies. The mechanism appears to involve the 5-HT2A receptor — the primary target of psilocybin — which, when activated, triggers downstream signaling cascades that promote protein synthesis and structural remodeling.
BDNF plays a central role in this process. Psilocybin appears to upregulate BDNF expression in prefrontal cortical regions, which is significant because BDNF is reduced in depression and other stress-related conditions. Whether psilocybin is clinically effective partly because of BDNF effects, or whether the BDNF change is incidental, remains an open question.
What Human Research Shows
Translating animal findings to humans is where caution is warranted. You cannot easily measure dendritic spine density or synaptogenesis in living human brains. Researchers instead rely on neuroimaging — primarily fMRI — to study functional connectivity, and on biomarkers like blood BDNF levels as an indirect proxy.
Human neuroimaging studies have consistently shown that psilocybin disrupts default mode network (DMN) activity during acute experience. The DMN is the brain's "self-referential" network, active during rumination, self-focused thought, and autobiographical memory retrieval. Its disruption is associated with the ego-dissolution and time-distortion reported during psilocybin experiences.
More importantly for therapeutic claims, studies at Johns Hopkins and Imperial College London found that psilocybin produces lasting changes in functional connectivity — not just during the experience, but days and weeks afterward. Patterns of connectivity become more flexible and less entrenched, particularly in networks associated with rigid, repetitive thought (a hallmark of depression, OCD, and PTSD).
A 2023 study in Nature Medicine by Daws and colleagues used a metric called "brain entropy" — the diversity and unpredictability of brain activity patterns — and found psilocybin increased entropy acutely, with some increases persisting weeks later in treatment responders. Higher brain entropy correlates with cognitive flexibility.
The BDNF Question
Several clinical studies have measured BDNF levels in blood before and after psilocybin treatment. Results have been mixed. Some studies show BDNF increases in treatment responders; others show no significant change. Blood BDNF levels are only weakly correlated with brain BDNF, so these measurements have limited interpretive value.
The most honest statement is: animal research strongly supports psilocybin-driven BDNF increases and structural neuroplasticity; human evidence is consistent with this but cannot directly confirm it.
Critical Caveats
Effect sizes in animals may not translate. The doses used in some preclinical plasticity studies are high relative to clinical human doses. The relationship between dose, receptor activation, and structural change may not scale linearly.
Correlation vs. causation in imaging studies. Changes in functional connectivity after psilocybin treatment could reflect neuroplasticity, but they could also reflect changes in mood, cognition, or simply regression to the mean in treatment-responsive patients.
Duration of effects. Preclinical plasticity effects are often measured 24-72 hours after treatment. It is unclear how long structural changes persist, whether they require reinforcement through integration practices, and whether they differ between single and repeated dosing.
Individual variation. Not everyone responds to psilocybin with the same functional connectivity shifts. The factors predicting who shows lasting neuroplasticity changes are not well understood.
What This Means Practically
The neuroplasticity framing helps explain why psilocybin therapy pairs psychological support with the drug experience. If psilocybin opens a window of increased neural flexibility, what happens during and after the experience may matter enormously. Therapy, integration work, and intentional reflection may be how the brain uses that plasticity to form new, healthier patterns.
This is why most clinical protocols treat psilocybin as a catalyst within a therapeutic process — not a standalone treatment. The drug may create the conditions for change; the work of therapy is what the change gets directed toward.
Summary
The evidence for psilocybin promoting neuroplasticity is real but nuanced. Preclinical findings are robust: psilocybin promotes dendritic growth, synaptogenesis, and BDNF expression in animal and cell models. Human neuroimaging consistently shows lasting functional connectivity changes in treatment responders. However, the exact mechanisms in humans, the duration of structural changes, and the relationship between neuroplasticity and clinical outcomes remain active research questions. The science supports cautious optimism — not breathless certainty.